News zu MAAT PHARMA S.A. EO-,1

MaaT Pharma and Skyepharma Have Entered a Partnership to Establish the First Exclusive Microbiome Ecosystem Therapies cGMP Manufacturing Facility in France · Uhr · Business Wire
MaaT Pharma Announces Ordinary and Extraordinary Shareholders’ General Meeting on March 3, 2022, and the Availability of Preparatory Documents · Uhr · Business Wire
MaaT Pharma Announces Positive Interim Engraftment Data for Oral Formulation MaaT033 Allowing Early Termination of Phase 1b CIMON Study · Uhr · Business Wire
MaaT Pharma Provides Business Objectives and Expected Milestones for 2022 · Uhr · Business Wire
MaaT Pharma Announces Initiation of Coverage of its Stock by KBC Securities, Kempen and Portzamparc/Groupe BNP Paribas · Uhr · Business Wire
MaaT Pharma to Present at H.C. Wainwright BioConnect 2022 Virtual Conference · Uhr · Business Wire
MaaT Pharma Presents Promising Clinical Data from 76 Patients with Acute Graft-vs-Host-Disease Treated with MaaT013 at 63rd ASH Annual Meeting · Uhr · Business Wire
MaaT Pharma Will Host Investor Information Meeting Following Presentation at ASH Conference of Additional Results on MaaT013 · Uhr · Business Wire
MaaT Pharma to Provide Additional Results from Phase II Trial and Expanded Access Program on MaaT013 in Oral Presentation at 63rd American Society of Hematology (ASH) Annual Meeting · Uhr · Business Wire